Company overview
InnoSIGN provides OncoSIGNal pathway profiling services as a CLIA-validated Laboratory Developed Test (LDT) for quantifying activity of key signaling pathways like ER, AR, PI3K, MAPK, Hedgehog, Notch, and TGFß in cancer tissue samples. The platform supports pharma R&D and clinical users with RNA-seq data analytics to identify tumor-driving pathways and guide targeted therapies, initially validated for breast cancer with expansions underway. It also offers a portal for secure, on-demand analysis of multi-omics data to interpret disease mechanisms.
InnoSIGN is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include oncosignal, pathway profiling, precision oncology, rna-seq analytics, clia ldt.
Structured facts
- Website
- https://www.innosignbio.com
- Markets served
- United States & Americas
- Keywords
- oncosignal, pathway profiling, precision oncology, rna-seq analytics, clia ldt
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is OncoSIGNal and what pathways does it profile?
- OncoSIGNal is a platform that quantifies functional activity of ER, AR, PI3K, MAPK, Hedgehog, Notch, and TGFß signaling pathways in tumor tissue, identifying aberrant tumor-driving activity relative to reference ranges to guide therapies.
- Is OncoSIGNal available for clinical use and what is its regulatory status?
- Yes, OncoSIGNal is offered as a Laboratory Developed Test (LDT) through InnoSIGN’s high-complexity CLIA laboratory in the US, validated for breast cancer with development for other types ongoing.
- What services does InnoSIGN provide for pharma R&D?
- InnoSIGN offers testing services, RNA-seq data analytics, and a secure portal for functional pathway analysis from multi-omics data to empower pharmaceutical research, drug development, and clinical decision-making.
Related editorial coverage
- FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
- Next-Generation Sequencing MEA: Impact on Precision Oncology Treatment Selection
- AACR 2026: ctDNA, Immunotherapy, and KRAS Target Breakthroughs
Explore lab tools and QA/QC resources for R&D teams.
